• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Smurf1 Knockdown Drives Liver Failure via Ferroptosis

by
November 7, 2026
in Biology, Health
Reading Time: 6 mins read
0
Smurf1 Knockdown Drives Liver Failure via Ferroptosis

Smurf1 Knockdown Drives Liver Failure via Ferroptosis

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have identified a specific molecular mechanism linking the E3 ubiquitin ligase Smurf1 to the progression of acute liver failure. In a study published in the Journal of Cellular and Molecular Medicine, the team demonstrated that reducing the expression of Smurf1 promotes a form of regulated cell death known as ferroptosis in liver cells. This process is driven by the inhibition of ubiquitin-mediated degradation of the protein Ulk1, which subsequently activates autophagy-dependent pathways that exacerbate liver injury.

Acute liver failure is a severe clinical syndrome characterized by the massive necrosis of hepatocytes and a significant impairment of liver function. Currently, there are no effective medical treatments available for this condition, and existing therapeutic strategies primarily focus on reducing hepatocyte death. While cell death in the liver has traditionally been understood through the lenses of apoptosis or necrosis, recent research has defined several other forms of programmed cell death. Among these, ferroptosis has attracted increasing attention due to the liver’s susceptibility to oxidative damage and the frequent accumulation of iron in liver diseases.

Ferroptosis is a non-apoptotic form of regulated cell death caused by the excessive accumulation of phospholipid peroxides. These peroxides are generated from the oxidation of polyunsaturated fatty acyl moieties in membrane phospholipids and are catalyzed by iron-dependent mechanisms. Following the onset of liver failure, a large number of cells die, leading to an abnormal accumulation of free iron. This excess free iron induces oxidative stress and ferroptosis through the Fenton reaction, which further aggravates hepatocyte death. Consequently, inhibiting ferroptosis is considered a potential strategy to improve hepatocyte survival and suppress the progression of liver failure.

The study utilized a mouse model of acute liver failure established by intraperitoneal injection of lipopolysaccharide and D-galactosamine into male C57BL/6 mice. The researchers confirmed the presence of ferroptosis in these mice through biochemical assays and histological analysis. They observed increased concentrations of Fe2+ and malondialdehyde, alongside decreased expression of the proteins Fth1 and Gpx4. Treatment with the ferroptosis inhibitor Liproxstatin-1 significantly improved the progression of liver failure and reduced ferroptosis levels in the liver tissues, confirming the key role of this cell death pathway in the disease.

To identify the molecular regulators involved, the researchers performed proteomic analysis on liver tissues from mice treated with the ferroptosis inhibitor. The analysis revealed that the E3 ubiquitin ligase Smurf1 was significantly upregulated after treatment, suggesting a potential role in liver failure-related ferroptosis. Further verification showed that Smurf1 expression was significantly lower in the acute liver failure mouse model compared to normal controls. Similarly, in a HepaRG cell ferroptosis model, the protein expression of Smurf1 was significantly reduced, indicating that Smurf1 is downregulated in the state of liver failure.

The ubiquitin-proteasome system is a widely existing protein modification and degradation pathway in cells, where E3 ubiquitin ligases serve as key enzymes that determine the specific recognition of target proteins. The study found that Smurf1 directly interacts with a novel substrate protein named Ulk1. Ulk1 is recognized as an initiator of autophagy, a process involving the degradation of cellular components via lysosomes to maintain cellular homeostasis. Co-immunoprecipitation experiments confirmed that Smurf1 can interact with Ulk1 in hepatocytes, and subsequent experiments showed that Smurf1 promotes the ubiquitin-dependent degradation of Ulk1.

When Smurf1 was knocked down using lentiviral shRNA in HepaRG cells, the ubiquitination level of Ulk1 was significantly reduced, maintaining its protein stability. This stabilization of Ulk1 led to the activation of the autophagic pathway. The researchers observed that Smurf1 knockdown increased the expression of LC3II and decreased the protein level of P62, markers indicative of activated autophagy. Conversely, overexpression of Smurf1 inhibited autophagy. This suggests that Smurf1 normally functions to suppress autophagy by promoting the degradation of its initiator, Ulk1.

Autophagy is considered an upstream mechanism of ferroptosis because its activation can degrade ferritin to release free iron. This release of free iron mediates the Fenton reaction, resulting in the accumulation of lipid reactive oxygen species and the aggravation of ferroptosis. The study demonstrated that Smurf1 knockdown promoted hepatocyte ferroptosis by activating Ulk1-mediated autophagy. When Ulk1 was also knocked down in the presence of Smurf1 knockdown, the pro-ferroptotic effect was reversed, confirming that the promotion of ferroptosis by Smurf1 knockdown is dependent on the activation of Ulk1-mediated autophagy.

In the mouse model, the researchers used an adeno-associated virus to downregulate Smurf1 expression specifically in the liver. They found that Smurf1 knockdown exacerbated liver failure, as evidenced by increased levels of serum alanine transaminase and aspartate aminotransferase, as well as more severe pathological changes in liver tissue observed through hematoxylin and eosin staining. These in vivo results align with the in vitro findings, suggesting that Smurf1 knockdown may exacerbate the progression of liver failure by promoting hepatocyte ferroptosis.

The mechanism involves Smurf1 catalyzing the formation of K48-linked ubiquitin chains on Ulk1, which signals for its degradation. When Smurf1 is present, Ulk1 levels are kept low, thereby limiting autophagy. However, when Smurf1 is knocked down, Ulk1 is stabilized, leading to elevated autophagy. This increased autophagic activity degrades ferritin, releasing a large amount of free iron that leads to the abnormal accumulation of reactive oxygen species and induces ferroptosis of hepatocytes.

The study highlights the Smurf1-Ulk1 axis as a potential therapeutic target for regulating ferroptosis in liver failure. By understanding how Smurf1 regulates the stability of Ulk1, researchers can develop strategies to modulate this pathway. For instance, enhancing Smurf1 activity or stabilizing Ulk1 degradation could potentially inhibit the autophagy-dependent ferroptosis that contributes to acute liver failure. This provides new insights into the complex molecular mechanisms underlying liver injury.

While the study provides strong evidence for the role of the Smurf1-Ulk1 axis in ferroptosis, it is important to note that ferroptosis of hepatocytes after liver failure is a complex process. The molecular mechanisms require further in-depth study to fully elucidate all contributing factors. The findings are based on specific mouse models and cell lines, and further validation in other contexts may be necessary. Nevertheless, the identification of this specific pathway offers a promising direction for future therapeutic development in the treatment of acute liver failure.

Beyond acute liver injury, the E3 ubiquitin ligase Smurf1, known formally as Smad ubiquitination regulatory factor 1, participates in several distinct hepatic and systemic processes. Prior studies demonstrated that Smurf1 inhibits hepatocellular carcinoma progression by regulating the ubiquitination of UVRAG and alleviates hepatic steatosis by targeting PPARγ for ubiquitin-mediated degradation. The ligase also regulates bone homeostasis, cell migration, and iron metabolism across different tissues. For instance, earlier work established that Smurf1 promotes the ubiquitination and degradation of FTH1 to maintain iron balance in skeletal muscle. In neurological settings, Smurf1 has been reported to promote neuronal necrosis and ferroptosis following lipopolysaccharide-induced neuroinflammation, yet it inhibits ferroptosis in models of Alzheimer’s disease by facilitating the ubiquitination and degradation of GDF15 to activate NRF2. These divergent findings reflect the diverse cellular roles played by Smurf1 depending on the specific substrate recognized by the enzyme.

To uncover how Smurf1 acts in acute liver failure, the researchers identified its downstream partner through a multi-step screening strategy. They performed immunoprecipitation followed by mass spectrometry on protein extracts from HEK 293T and HepaRG cells to map physical binding partners. The authors then cross-referenced these candidate proteins against computational predictions from the UbiBrowser database and ferroptosis-associated disease datasets, pinpointing Ulk1 as a common target. Crucially, modulating Smurf1 expression altered Ulk1 protein abundance without altering its messenger RNA expression, confirming that regulation occurs at the post-translational level. Experiments using cycloheximide to halt new protein synthesis verified that Smurf1 accelerated Ulk1 degradation, while treatment with the proteasomal inhibitor MG132 reversed this decline. In addition, immunohistochemical examination of liver specimens revealed that Ulk1 expression was significantly higher in mice with acute liver failure than in normal controls.

Specific in vitro assays provided additional biochemical detail regarding the role of Smurf1 during lipid peroxidation. Cultured HepaRG hepatocytes were exposed to erastin at a concentration of 10 micromolar for 24 hours to stimulate ferroptotic death. Under these conditions, knocking down Smurf1 markedly suppressed levels of the cystine-glutamate antiporter component Slc7a11 as well as Fth1, while boosting ferrous iron concentration and malondialdehyde generation. In animal trials supervised by the Laboratory Animal Committee of Nanchang University, the research team administered an adeno-associated virus delivering short hairpin RNA against Smurf1 through tail-vein injection at a titer of 60 billion viral genomes. For all quantitative comparisons, the authors conducted at least three independent experimental replicates, analyzing the data using unpaired two-tailed Student’s t-tests or analysis of variance alongside Tukey’s post hoc tests to establish statistical significance.

The involvement of Ulk1 connects these liver findings to a growing body of literature examining autophagy-dependent ferroptosis across multiple tissue pathologies. Ulk1 functions as an essential initiator of autophagy whose activity triggers autophagosome assembly, whereas its inactivation halts the autophagic response. Prior investigations demonstrated that Ulk1 promotes cardiomyocyte ferroptosis during cardiac hypertrophy through the HMGA2, METTL14, and SLC7A11 regulatory pathway. Similarly, exposure to acrylamide has been shown to induce autophagy-dependent ferroptosis in human chondrocytes by activating AMPK-ULK1-MTOR signaling. Within hepatocytes, excessive autophagic activity degrades ferritin molecules to release free catalytic iron, which fuels the Fenton reaction and generates toxic lipid reactive oxygen species. By outlining how reduced Smurf1 expression impedes Ulk1 degradation and permits sustained autophagic turnover, the current study clarifies an intricate biochemical network governing regulated cell death in acute liver failure.

Subject of Research: Molecular mechanism of Smurf1-mediated regulation of ferroptosis in acute liver failure

Article Title: Knockdown of Smurf1 Promotes Autophagy‐Dependent Ferroptosis in Acute Liver Failure by Inhibiting Ubiquitin‐Mediated Ulk1 Degradation

Article References: Shi, P., Tao, M., Zeng, Y., Peng, Y., & Wu, X. (2026). Knockdown of Smurf1 Promotes Autophagy‐Dependent Ferroptosis in Acute Liver Failure by Inhibiting Ubiquitin‐Mediated Ulk1 Degradation. Journal of Cellular and Molecular Medicine, 30(21), Article e71405. https://doi.org/10.1111/jcmm.71405

Image Credits: AI Generated

DOI: 10.1111/jcmm.71405

Keywords: acute liver failure, ferroptosis, Smurf1, Ulk1, autophagy, hepatocytes, ubiquitin-proteasome system, cell death, liver disease, molecular biology, Knockdown, Promotes

News Source: Drew Townsend. (November 7, 2026). Smurf1 Knockdown Drives Liver Failure via Ferroptosis. Scienmag.

Tags: acute liver failureautophagyCell Deathferroptosishepatocytesknockdownliver diseaseMolecular BiologypromotesSMURF1ubiquitin-proteasome systemULK1
Share12Tweet7Share2ShareShareShare1

Related Posts

Cerebral Infarctions Reveal Hypereosinophilic Syndrome in Patient with Loeffler Endocarditis

Cerebral Infarctions Reveal Hypereosinophilic Syndrome in Patient with Loeffler Endocarditis

November 18, 2026
Stem Cell Reports Named Official Meeting Journal for Organoids Are Us 2027

Stem Cell Reports Named Official Meeting Journal for Organoids Are Us 2027

November 18, 2026

Intestinal Cellular Networks Govern Fibroblast Plasticity in Healing and Fibrotic Disease

November 18, 2026

Extended-Interval Myeloma Antibody Therapy Safely Omits Repeat Step-Up Dosing in Cohort

November 18, 2026

POPULAR NEWS

  • Over Forty Percent of Northeast Ethiopian Neonates Experience Early Cord Clamping

    Over Forty Percent of Northeast Ethiopian Neonates Experience Early Cord Clamping

    29 shares
    Share 12 Tweet 7
  • Biomimetic Hydroxyapatite Coating Restores Elastic Modulus in Recycled Aggregate Concrete

    29 shares
    Share 12 Tweet 7
  • Early Shoulder Mobilization Accelerates Initial Motion but Yields Equivalent Annual Outcomes

    29 shares
    Share 12 Tweet 7
  • SGLT2 Inhibitor Use Associated With Lower Proteinuria Rates During Bevacizumab Therapy

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cerebral Infarctions Reveal Hypereosinophilic Syndrome in Patient with Loeffler Endocarditis

Stem Cell Reports Named Official Meeting Journal for Organoids Are Us 2027

Nitrogen-Doped Graphene Underlayer Lowers Overpotential in Aluminum-Doped Hematite Water Splitting

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.